Teva and mabxience expand strategic partnership to include an additional oncology biosimilar candidate

Tel aviv, israel and madrid, oct. 03, 2024 (globe newswire) -- teva pharmaceuticals international gmbh, a subsidiary of teva pharmaceutical industries ltd. (nyse and tase: teva) and mabxience, a fresenius kabi majority-owned group with partial ownership from insud pharma, today announced a new global licensing agreement for the development of an anti pd-1 oncology biosimilar candidate. this marks the second agreement between the two companies, reinforcing the solid foundation of the collaborative efforts that commenced in april 2024.
TEVA Ratings Summary
TEVA Quant Ranking